![william whitehead md baylor college of medicine email william whitehead md baylor college of medicine email](https://fannininnovation.com/wp-content/uploads/2019/12/Michael-Belfort.png)
Tumor size alone accounted for a significant amount of unique variance in FSIQ ( Δ R 2 = 0.065), PRI ( Δ R 2 = 0.076), and PSI ( Δ R 2 = 0.080), beyond that captured by the NPS and relevant covariates. The NPS significantly predicted Full-Scale Intelligence Quotient (FSIQ Δ R 2 = .079), Verbal Comprehension Index (VCI Δ R 2 = 0.051), Perceptual Reasoning Index (PRI Δ R 2 = 0.065), and Processing Speed Index (PSI Δ R 2 = 0.049) performance after controlling for sex, age at diagnosis, and maternal education. Participants (51% female) aged 6-20 years ( M = 13.22, SD = 4.09) completed neurocognitive evaluations 5.16 years ( SD = 1.29) postdiagnosis. Hierarchical multiple regressions examined the predictive and incremental validity of NPS score, tumor location, and tumor size.
![william whitehead md baylor college of medicine email william whitehead md baylor college of medicine email](https://signature.bcm.edu/images/uploaded/profile/1465833115734.jpeg)
Survivors ( N = 69) diagnosed from 2010 to 2016 were administered age-appropriate versions of the Wechsler Intelligence Scales.
![william whitehead md baylor college of medicine email william whitehead md baylor college of medicine email](https://www.houstonent.com/hs-fs/hubfs/Houston_April2017/images/members/StanfordMarvinShoss.jpg)
This study evaluated the predictive validity of the NPS, and the incremental value of tumor location and size, for neurocognitive outcomes in early survivorship following contemporary therapies for pediatric brain tumors. The Neurological Predictor Scale (NPS) quantifies cumulative exposure to conventional treatment-related neurological risks but does not capture potential risks posed by tumors themselves.